Help Patients Stick With a Statin...Instead of the New PCSK9 inhibitors

October 2015

The new PCSK9 inhibitor, Repatha (rih-PATH-ah, evolocumab), will raise questions about how to help patients stick with a statin.

Repatha is similar to Praluent (alirocumab).

Both PCSK9 inhibitors are injectable biologics...may lower LDL about 60%...cost about $14,000/yr...and lack long-term outcome and safety data.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: MD includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote